NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 17 February 2022 at 9:30am

**Location:** Via Zoom

## Attendees

Committee members present

1. Charles Crawley (Chair) Present for all items
2. Sanjeev Patel (Vice Chair) Present for all items
3. Anna Pracz Present for all items
4. Gabriel Rogers Present for all items
5. Iolo Doull Present for all items
6. James Fotheringham Present for all items
7. Mark Glover Present for all items
8. Mary Weatherstone Present for all items
9. Nicholas Latimer Present for all items
10. Nicky Welton Present for all items
11. Nigel Westwood Present for all items
12. Peter Wheatley Price Present for all items
13. Rhiannon Owen Present for all items
14. Toby Smith Present for all items
15. Tony Wootton Present for all items
16. Veline L’Esperance Present for all items

NICE staff present

Natalie Spray, Programme Manager Present for 5 to 6.1.1

Henry Edwards, Associate Director Present for 1 to 4.3.2, 5.2 & 6.1

Richard Diaz, Associate Director Present for 5 to 6.1.2

Jeremy Powell, Project Manager Present for 1 to 4.3.1

Yelan Guo, Technical Advisor Present for all items

Charlie Hewitt, Technical Advisor Present for items 1 to 4.3.1

Harsimran Sarpal, Technical Analyst Present for 1 to 4.3.1

Becca Thomas, Technical Analyst Present for items 5 to 5.3.1

Hayley Garnett, Senior Medical Editor Present for items 1 to 4.3.2

Claire Hawksworth, TA Commercial Risk Present for 5 to 5.3.1

Lyn Davis, Coordinator, MiP Present for 1 to 4.1.3

Rosalee Mason, Coordinator, MiP Present for 1 to 4.1.3

Laura Marsden, Advisor, PiP Present for items 1 to 4.3.1

Emma Gordon, Administrator, TA Team Present for items 5 to 6.1.1

Rumana Zaman, Administrator, TA Team Present for 1 to 4.3.2

Laura Kelly, Administrator, COT Present for all items

External assessment group representatives present

Maiwenn Al, Kleijnen Systematic Reviews Present for items 1 to 4.2.1

Rob Riemsma, Kleijnen Systematic Reviews Present for items 1 to 4.2.1

Sabine Grimm, Kleijnen Systematic Reviews Present for items 5 to 5.2

Nigel Armstrong, Kleijnen Systematic Reviews Present for items 5 to 5.2

Experts present

Zoe Paskins, Clinical Expert Present for items 1 to 4.1.3

Dr Nicola Peel, Clinical Expert Present for items 1 to 4.1.3

Dr Peter Clark, Clinical Expert Present for items 5 to 5.3.1

Lauren Wiggins, Patient Expert Present for items 5 to 5.2

Christine Sharp, Patient Expert Present for items 5 to 5.2

Observers present

Amanda Adler, Chair, NICE Antimicrobials Committee Present for all items

Philip Williams, Finance/Business Analyst, NICE Present for items 1 to 5.2.1

Sam Slayen, Technical Analyst Present for items 1 to 5.3.1

Korin Knight, Senior Medical Editor Present for items 5 to 6.1.1

Anna Sparshatt, Senior Editor, Digital Publishing Present for items 5 to 6.1.1

Heather Stegenga, Heath Technology Analyst Present for items 5 to 5.3.2

Emily Eaton-Turner, TA Commercial Risk Present for 5 to 5.3.1

Ella Livingstone, TA Commercial Risk Present for 1 to 5.3.1

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Carlo Berti, Denise Bryceland, Maria Bretzitski, Stuart Williams. Apologies from Laura Bojke and Stephen Smith were noted after the meeting.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on 4 November 2021, 8 December 2021 and 20 January 2022.

### Appraisal of Romosozumab for treating severe osteoporosis [ID3936]

* 1. Part 1 – Open session
     1. The vice chair welcomed the invited professional experts, external assessment group representatives, members of the public and company representatives from UCB Pharma.
     2. The vice chair asked all committee members, professional experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

Nicholas Latimer declared an indirect financial interest, as of May 2021 they have been a member of the ScHARR team for a consultancy project involving the adjustment for treatment switching observed in the NETTER-1 trial, comparing lutathera to best supportive care alone in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumours. Lutathera is made by Advanced Accelerator Applications (AAA) Ltd, a Novartis company. Novartis are listed as a comparator company. Furthermore, In October 2021 Dr Latimer gave Novartis staff a training session on survival analysis. This was not product or appraisal specific and was about methods. It was agreed that this declaration wouldn’t prevent them from participating in this discussion.

James Fotheringham declared a direct financial interest, as in March 2021 they chaired a session on kidney transplant survival prediction sponsored by Novartis. It was agreed that this declaration wouldn’t prevent them from participating in this discussion.

Prior to the meeting, Expert Nicola Peel declared a direct financial interest as they receive a Lecture fee from University of Derby for single teaching session each year on DXA reporting course, and Honoraria to teach on the annual BRS Oxford training course. Dr Peel has been a participant in Yorkshire Bone Network (formerly East Pennines Osteoporosis Interest Group) – 6-monthly meetings supported by Amgen (room hire & catering, no personal remuneration) and had Involvement in planning and acted as moderator for series of 3 ROS webinars July 2020 which were supported by UCB (no personal remuneration.) Ended 2019: Chair of Sheffield Osteoporosis Working Group – quarterly meetings supported by Amgen (room hire & catering, no personal remuneration) Honoraria from Amgen for speaker meetings – most recently in 2010. Nicola Peel also declared a direct non-financial interest, as they had acted as Peer reviewer for National Osteoporosis Guideline Group revised guidance (in preparation 2021.) During the meeting, Dr Peel declared and an indirect interest as they have been appointed as Topic Advisor for the NICE Osteoporosis Guideline committee (from Oct 2021). It was agreed that this declaration wouldn’t prevent them from participating in this discussion.

Zoe Paskins declared a direct non-financial interest as they are a Member of National Osteoporosis Guideline Group, a committee member for Royal Osteoporosis Society and has undertaken non-promotional consultancy for UCB but waived right to, and did not receive any financial honoraria. It was agreed that this declaration wouldn’t prevent them from participating in this discussion.

* + 1. The Vice Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2a – Closed session (members of the public, company representatives and the clinical and patient experts were asked to leave the meeting)
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting)
     1. The committee asked the NICE technical team to prepare the documents in line with their decisions and further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10828>

### Appraisal of Nivolumab with ipilimumab for untreated resectable malignant pleural mesothelioma [ID1609] (Part 2 only)

* 1. Part 2a – Closed session (members of the public were not present.)
     1. The chair welcomed the invited professional experts, external assessment group representatives, and company representatives from Bristol-Myers Squibb.
     2. The Chair asked all committee members, professional experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

Nicholas Latimer declared an indirect financial interest, as of May 2021 they have been a member of the ScHARR team for a consultancy project involving the adjustment for treatment switching observed in the NETTER-1 trial, comparing lutathera to best supportive care alone in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumours. Lutathera is made by Advanced Accelerator Applications (AAA) Ltd, a Novartis company. Novartis are listed as a comparator company. Furthermore, In October 2021 Nicholas Latimer gave Novartis staff a training session on survival analysis. This was not product or appraisal specific and was about methods. It was agreed that this declaration wouldn’t prevent them from participating in this discussion.

James Fotheringham declared a direct financial interest, as in March 2021 they chaired a session on kidney transplant survival prediction sponsored by Novartis. It was agreed that this declaration wouldn’t prevent them from participating in this discussion.

* 1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (external assessment group representatives and company representatives were asked to leave the meeting).
     1. The committee asked the NICE technical team to prepare the documents in line with their decisions and further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10498>

### Appraisal of Diroximel fumerate for treating relapsing-remitting multiple sclerosis [ID1673]

* 1. Part 2b – Closed session.

James Fotheringham declared a direct financial interest, as in March 2021 they chaired a session on kidney transplant survival prediction sponsored by Novartis. It was agreed that this declaration wouldn’t prevent them from participating in this discussion.

* + 1. The committee asked the NICE technical team to prepare the documents in line with their decisions and further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10714>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Thursday 17 March 2022 and will start promptly at 9:30am.